These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 26893067)
1. Signalling: Putting the brakes on KRAS-G12C nucleotide cycling. Shipman L Nat Rev Cancer; 2016 Mar; 16(3):127. PubMed ID: 26893067 [No Abstract] [Full Text] [Related]
2. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Lito P; Solomon M; Li LS; Hansen R; Rosen N Science; 2016 Feb; 351(6273):604-8. PubMed ID: 26841430 [TBL] [Abstract][Full Text] [Related]
3. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS Xiao X; Lai M; Song Z; Geng M; Ding J; Xie H; Zhang A Eur J Med Chem; 2021 Mar; 213():113082. PubMed ID: 33309163 [TBL] [Abstract][Full Text] [Related]
6. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Canon J; Rex K; Saiki AY; Mohr C; Cooke K; Bagal D; Gaida K; Holt T; Knutson CG; Koppada N; Lanman BA; Werner J; Rapaport AS; San Miguel T; Ortiz R; Osgood T; Sun JR; Zhu X; McCarter JD; Volak LP; Houk BE; Fakih MG; O'Neil BH; Price TJ; Falchook GS; Desai J; Kuo J; Govindan R; Hong DS; Ouyang W; Henary H; Arvedson T; Cee VJ; Lipford JR Nature; 2019 Nov; 575(7781):217-223. PubMed ID: 31666701 [TBL] [Abstract][Full Text] [Related]
7. RAS G12C Inhibitors: Three Birds with One Stone. Seale T; Misale S Cancer Discov; 2024 May; 14(5):698-700. PubMed ID: 38692265 [TBL] [Abstract][Full Text] [Related]
8. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors. Stites EC; Shaw AS CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842 [TBL] [Abstract][Full Text] [Related]
14. Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents. Li L; Zhao H; Liao H; Chen J; Liu J; Chen J Bioorg Chem; 2021 May; 110():104825. PubMed ID: 33774492 [TBL] [Abstract][Full Text] [Related]
15. Direct KRAS inhibition: progress, challenges, and a glimpse into the future. Grapsa D; Syrigos K Expert Rev Anticancer Ther; 2020 Jun; 20(6):437-440. PubMed ID: 32320301 [No Abstract] [Full Text] [Related]
16. After decades, progress against an 'undruggable' cancer target. Kaiser J Science; 2019 Nov; 366(6465):561. PubMed ID: 31672875 [No Abstract] [Full Text] [Related]